Candida albicans is the most common causative agent of oral candidiasis in human immunodeficiency virus (HIV)-infected patients (5) . During the course of HIV infection, 36 to 88% of all patients suffer from oral candidiasis (4, 15, 21) . In one clinical trial, it was shown that the development of oral candidiasis in patients at an early stage of HIV infection might promote the onset of full-blown acquired immunodeficiency syndrome (AIDS) (9) .
Despite the high prevalence of oral candidiasis and its relative importance for the further development of HIV infection, no systematic studies of antifungal susceptibility and biotype identification of the C. albicans strains involved have been conducted.
The new imidazole derivatives, among them ketoconazole and itraconazole, have been proven highly active against candidiasis in vivo. Conventional in vitro susceptibility testing, however, could never confirm this feature (7, 14) and is therefore of limited value for the evaluation of the antifungal activity of these agents. This is mainly because of partial inhibition of growth over a wide range of drug concentrations (7) . As imidazoles such as ketoconazole are among the drugs of choice for the treatment of oral candidiasis in HIV-infected patients, a method has to be employed for antifungal susceptibility testing which avoids the mentioned problem, facilitates large-scale testing, and leads to reliable results both with imidazoles and other antifungal agents. The turbidimetric method first described by Galgiani and Stevens (3) and further developed by Johnson et al. (7) seemed to be very suitable for these purposes. It is a photometer-read broth microdilution method for determination of the 30% inhibitory concentration (IC30), i.e., the lowest drug concentration at which growth is just less than 30% of that in the positive control well.
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Although "there is no ideal laboratory procedure or culture medium in current use for susceptibility testing of pathogenic yeasts" (16) , this method, in principle, seems to be able to discriminate between those C. albicans strains which can be eradicated clinically and the others which cannot (7). This is a major advantage over other tests frequently used, such as the agar dilution test (7; for a more detailed discussion, see reference 11).
The commercially available API 20C carbohydrate assimilation system for yeast identification is widely used in clinical laboratories for biotyping C. albicans and serves because of its good reproducibility, sensitivity, and specificity as a reference system for the evaluation of new yeast identification systems (18) , although its discriminatory power is limited (22) .
In the present report, 88 HIV-infected patients consecutively seen in the outpatient clinic were examined for the oral presence of C. albicans. Isolated strains were identified, biotyped with the API 20C system, and evaluated for their susceptibility to five antifungal agents (ketoconazole, itraconazole, nystatin, amphotericin B, and flucytosine) by means of 'C30 determination. Clinical isolates and biotyping. Sixty-two C. albicans isolates were recovered from the oral cavities of the patients. Isolated strains were maintained on Kimmig agar slants at 4°C and subcultured monthly at 37°C for 24 h. Each C. albicans strain was identified by using both the Uni-YeastTek system (Flow Laboratories, Meckenheim, Federal Republic of Germany) (18) with an additional germ tube test and the API 20C system (Api Bio Mérieux, Nurtingen, Federal Republic of Germany). The latter was used with the method of Williamson et al. (22) .
Antifungal agents. The five antifungal agents used for susceptibility testing of C. albicans isolates were amphotericin B (Sigma Chemical Co., St. Louis, Mo.), nystatin (Sigma), flucytosine (Sigma), ketoconazole (Janssen, Beerse, Belgium), and itraconazole (Janssen). All the substances were supplied as working standards for laboratory use. Stock solutions were prepared as follows: amphotericin B and nystatin were dissolved in dimethylformamide to a concentration of 3.200 ,ug of active drug per ml and stored in the dark at 4°C for a maximum of 7 days, flucytosine was dissolved in sterile distilled water to a concentration of 12.800 ,ug/ml and stored in small portions at -20°C, and ketoconazole and itraconazole were each solubilized in dimethyl sulfoxide substituted with 15 ,ul of 6 M HCl per ml (12) to a concentration of 12.800 ,ug/ml and kept at 4°C.
IC. susceptibility testing. For preparing the inoculum, Candida cells were grown to the synchronous stage as described by Soll and Bedell (20) with minor modifications. Blastoconidia from a 24-h Kimmig agar slant culture grown at 24°C were washed twice and suspended in sterile phosphate-buffered saline, pH 7.4; this suspension was inoculated into modified Sabouraud liquid medium containing 1% (wt/vol) mycological peptone (Oxoid, Wesel, Federal Republic of Germany) and 0.2% (wt/vol) glucose, pH 5.1, resulting in a final cell concentration of 2 x 105/mi, and incubated for 16 h at 24°C in a shaking water bath set at 150 rpm. A portion of this culture was transferred to fresh liquid medium, giving a final cell count of 4 x 106/ml, and incubated under the same conditions for 24 h. Finally, cells were washed three times in phosphate-buffered saline and suspended to a concentration of 107 cells per ml.
Serial twofold dilutions of all five antifungal agents were prepared in buffered yeast-nitrogen base (Difco Laboratories, Detroit, Mich.) as described by Shadomy et al. (19) . Drug concentrations ranged from 128 to 0.063 ,ug/ml. Susceptibility testing was performed in sterile round-bottom 96-well microdilution plates (Greiner Labortechnik, Nurtingen, Federal Republic of Germany). Each well was filled with 200 ,ul of either antifungal solution or yeast-nitrogen base without antifungal solution as a positive growth control. Plates were preincubated at 37°C for 20 min, and 10 ,ul of the prepared Candida suspension in phosphate-buffered saline (Table 1 ). The microbiological recovery of C. albicans from the oral cavity increased from 57.7% (seropositive latency) to 87.5% (AIDS) ( Table 1) .
The correlation between T4/T8 ratios and occurrence of clinical symptoms of oral candidiasis is given in Table 2 . From these data it is evident that the onset of oral candidiasis in HIV-infected patients correlates well with a reversed T4/T8 ratio. Only one patient with a ratio of >1 had clinical symptoms.
IC. determination. The distribution pattern of IC30s of each antifungal agent against the 62 isolated strains of C. albicans is shown in Fig. 1 Table 3 ). Resistance to flucytosine was observed with two strains (Fig. 5) , to itraconazole with three strains (Fig. 2) , and to ketoconazole with one strain (Fig. 1) With the two imidazoles, a higher prevalence of less susceptible strains was observed among patients with clinical symptoms for oral candidiasis. These strains (IC30s of .8 ,ug/ml for ketoconazole and -2 ,ug/ml for itraconazole) accounted for 29 and 33%, respectively, of strains recovered in patients with clinical symptoms but for only 11 and 13% in patients without symptoms (data not shown).
Biotypes. C. albicans strains were biotyped with the API 20C yeast identification system, which measures the carbohydrate assimilation abilities of C. albicans (22) . The major biotype (Bi; positive for xylose, adonitol, xylitol, sorbitol, methyl-D-glucoside, N-acetyl-D-glucosamine, sucrose, and trehalose; negative for glycerol, L-arabinose, and melezitose) accounted for 63.9% of all isolates. Of the minor biotypes (three special biotypes not described by Williamson et al. [22] named B,), B, was observed in 21.3%. Ail other biotypes were seen with a frequency of less than 5% (Table  4 ). A repeated evaluation was possible in 22 patients. A change in biotype pattern was seen in 6 patients (27.3%), whereas 10 patients (45.5%) presented with the same biotype at the follow-up. No significant correlation was found with a single biotype and IC30s. 
DISCUSSION
The 73.8% recovery of C. albicans from the oral cavities of HIV-infected patients determined in the present study is in good concordance with the recovery rates reported by others, which ranged from 36 to 88% (4, 15, 21) . Furthermore, the frequency of both cultural proof and clinical signs for oral candidiasis is clearly dependent on the stage of HIV infection, as has been shown recently (21) . This observation was confirmed in the present study, revealing a 57.7% microbiological recovery of C. albicans from the oral cavity of stage 1 patients, 76.5% from stage 2 patients, and 87.5% from stage 3 patients (Table 1) . Additional clinical signs for oral candidiasis were observed only in patients with PGL-ARC and AIDS (35.3 and 54.2%, respectively). The increasing recovery of Candida strains from patients with progressive HIV infection should be considered if quantitative laboratory tests are to be taken into account for decisions regarding patient treatment. Kaplan et al. (8) were able to demonstrate that the onset of oral candidiasis in HIVinfected patients is dependent on the absolute T4 cell count. In this trial, only one patient with a T4/T8 ratio of >1 suffered from clinically evident oral candidiasis, whereas all the other patients with clinical signs for oral candidiasis had a ratio of <1.
Somewhat surprising is the result that IC30s for flucytosine against C. albicans increase with progressive HIV infection. (19) . This situation is different from that observed with isolates from non-HIV-infected patients, of which the majority of Candida strains were highly susceptible to amphotericin B and only a minor percentage showed intermediate susceptibility (19) . In a given clinical situation, even these levels might be difficult to obtain on a regular scale by systemic treatment,' when the potentially severe side effects of the drug are considered. The routine application of a reliable and standardized biotyping system for Candida isolates from HIV-infected patients is highly desirable for the evaluation and localization of sources of infection, the determination of frequencies of changed biotype patterns, the selection of certain biotypes during therapy, and the differentiation between therapeutic failure and reinfection in cases of recurrent or persistent candidiasis. In this report, the commercially available API 20C system was applied to type Candida 'strains from HIV-infected patients. Unfortunately, as previously stated about strains from HIV-negative patients (22) ', the distribution of biotypes was very disproportionate, with 'a single group accounting for 63.9% of all isolates. In this respect, the system is of only limited use for biotyping C. albicans isolates from HIV-infected patients. In contrast to the results obtained by Williamson et al. (22) , a relatively high percentage of strains typed in the present study (21.3%) revealed distinctive carbohydrate assimilation patterns that were not seen by those authors. To ascertain if this feature is of any importance, additional biotyping systems with a higher discriminatory power, like the one described by Odds and Abbott (13) , must be applied.
In this study, the present susceptibility patterns of clinical C. albicans isolates from HIV-infected patients have been described for five major antifungal agents. Long-term antifungal therapy for oral candidiasis in patients with AIDS may result in decreased susceptibility of etiological agents. Data presented here suggest that antifungal-susceptibility studies may assist in the recognition of strains developing resistance during long-term therapy.
